Literature DB >> 2408658

Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura.

J F Delfraissy, G Tchernia, Y Laurian, C Wallon, P Galanaud, J Dormont.   

Abstract

Intravenous gammaglobulin (IVIgG) was given to seven adults with chronic idiopathic thrombocytopenic purpura (ITP). In parallel with platelet count, we studied Con A induced suppressor cell function for the autologous in vitro B cell response, T cell subsets and PAIgG levels, immediately before and 3-4 d after completion of treatment. Before treatment all patients had normal T cell subsets, decreased T suppressor cell function and increased levels of PAIgG. After IVIgG infusions, two patients were unresponsive and neither suppressor cell function nor PAIgG levels varied. In contrast, in the five responding patients we found an improvement in suppressor cell function and a decrease in PAIgG levels, while T cell subsets remained unmodified. Such results were reproducible in three patients after a second series of gammaglobulin infusions. Our results support the hypothesis that IVIgG infusion, apart from its effects on the reticuloendothelial system, may modulate the immune response by enhancing suppressor T cell function.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2408658     DOI: 10.1111/j.1365-2141.1985.tb07417.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  22 in total

Review 1.  [Chronic idiopathic thrombocytopenic purpura. Current therapy concept and introduction to pathophysiologic, clinical and diagnostic aspects].

Authors:  A Böcher; F G Hagmann; H Kreiter
Journal:  Med Klin (Munich)       Date:  1998-12-15

2.  Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro.

Authors:  I N van Schaik; I Lundkvist; M Vermeulen; A Brand
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

3.  Protective effect of a T-cell-dependent immunosuppressive, B-cell-mitogenic protein (F3'EP-Si, or P90) produced by Streptococcus intermedius.

Authors:  M Lima; A Bandeira; D Portnoi; A Ribeiro; M A Chaves
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

4.  The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids.

Authors:  W M Vuist; I N Van Schaik; M Van Lint; A Brand
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

5.  Stimulation of the respiratory burst and promotion of bacterial killing in human granulocytes by intravenous immunoglobulin preparations.

Authors:  L Maródi; A Kalmár; L Karmazsin
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

6.  Use of intravenous immunoglobulin in critically ill patients.

Authors:  Summer Donovan; Gonzalo M L Bearman
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

7.  Immunomodulating therapy of rheumatoid arthritis by high-dose intravenous immunoglobulin.

Authors:  H Becker; G Mitropoulou; K Helmke
Journal:  Klin Wochenschr       Date:  1989-03-01

Review 8.  Mechanism of action of intravenous immunoglobulin in immune-mediated cytopenias.

Authors:  H I Atrah; R J Davidson
Journal:  J Clin Pathol       Date:  1988-12       Impact factor: 3.411

9.  Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies.

Authors:  G Dietrich; M D Kazatchkine
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

Review 10.  Intravenous immune globulin in recurrent abortion.

Authors:  O Heine; G Mueller-Eckhardt
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.